{
    "organizations": [],
    "uuid": "1924f8f20a65134bf89648a1a6fcb8d3b8233f56",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ucb-to-present-phase-2b-findings-f/brief-ucb-to-present-phase-2b-findings-for-bimekizumab-idUSFWN1Q61BK",
    "ord_in_thread": 0,
    "title": "BRIEF-UCB To Present Phase 2b Findings For Bimekizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 41 PM / in 5 minutes BRIEF-UCB To Present Phase 2b Findings For Bimekizumab Reuters Staff 1 Min Read Feb 16 (Reuters) - Ucb Sa: * UCB ADVANCES PSORIASIS PIPELINE WITH POSITIVE DATA AT AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD 2018) * FULL EFFICACY AND SAFETY FINDINGS FROM PHASE 2B BE ABLE STUDY ON INVESTIGATIONAL MOLECULE BIMEKIZUMAB WILL HIGHLIGHT DUAL NEUTRALIZATION OF IL-17A AND IL-17F Source text for Eikon: Further company coverage: (Gdynia Newsroom:)",
    "published": "2018-02-16T17:40:00.000+02:00",
    "crawled": "2018-02-16T17:56:16.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "present",
        "phase",
        "2b",
        "finding",
        "bimekizumab",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "ucb",
        "sa",
        "ucb",
        "advance",
        "psoriasis",
        "pipeline",
        "positive",
        "data",
        "american",
        "academy",
        "dermatology",
        "annual",
        "meeting",
        "aad",
        "full",
        "efficacy",
        "safety",
        "finding",
        "phase",
        "2b",
        "able",
        "study",
        "investigational",
        "molecule",
        "bimekizumab",
        "highlight",
        "dual",
        "neutralization",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}